ADHDgene Database

Hot Results

Quick Search

Keyword:
Type:

Large-scale studies

Data Summary

Published Variant
- SNP: 1391
- CNV: 398
- Others: 173
Published Gene: 359
Published Region: 128
Pathway by PBA: 8
Study: 361

Detail ...

Gene Report

Basic Info

Approved Symbol	ERBB2
Previous Symbol	NGL
Symbol Alias	NEU, HER-2, CD340, HER2
Approved Name	v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)
Previous Name	v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog)
Location	17q11.2-q12
Position	chr17:37844393-37884915, +
External Links	HGNC: 3430 Entrez Gene: 2064 Ensembl: ENSG00000141736 UCSC: uc002hso.2
No. of Studies	0 (significant: 0; non-significant: 0; trend: 0)
Source	Mapped by LD-proxy

Gene related studies (count: 0)

Gene related SNPs (count: 10)

Literature-origin SNPs (count: 0)

LD-proxies (count: 10)

rs_ID	Location	Functional Annotation
rs2952156	Chr17:37876835(Fwd)	NMD_transcript_variant; downstream_gene_variant; intron_variant; nc_transcript_variant
rs1810132	Chr17:37866005(Fwd)	NMD_transcript_variant; downstream_gene_variant; intron_variant; nc_transcript_variant; upstream_gene_variant
rs1565923	Chr17:37858678(Fwd)	NMD_transcript_variant; intron_variant; nc_transcript_variant; upstream_gene_variant
rs2934971	Chr17:37854507(Fwd)	downstream_gene_variant; intron_variant; upstream_gene_variant
rs2952155	Chr17:37861718(Fwd)	NMD_transcript_variant; intron_variant; nc_transcript_variant; upstream_gene_variant
rs1058808	Chr17:37884037(Fwd)	3_prime_UTR_variant; NMD_transcript_variant; downstream_gene_variant; feature_truncation; frameshift_variant; missense_variant; upstream_gene_variant
rs2517955	Chr17:37843681(Fwd)	NMD_transcript_variant; intron_variant; nc_transcript_variant; upstream_gene_variant
rs903501	Chr17:37839493(Fwd)	NMD_transcript_variant; downstream_gene_variant; intron_variant; nc_transcript_variant; upstream_gene_variant
rs2517954	Chr17:37843550(Fwd)	NMD_transcript_variant; intron_variant; nc_transcript_variant; upstream_gene_variant
rs2517956	Chr17:37843859(Fwd)	NMD_transcript_variant; intron_variant; nc_transcript_variant; upstream_gene_variant

Gene related CNVs (count: 0)

Gene related other variant (count: 0)

Gene related regions (count: 0)

Gene related GO terms (count: 57)

GO terms by PBA (with statistical significance of FDR<0.05) (count: 0)

GO terms by database search (count: 57)

ID	Name	Type	Evidence[PMID]	No. of Genes in ADHDgene
GO:0070372	regulation of ERK1 and ERK2 cascade	Biological Process	IMP[16314522]	4
GO:0050679	positive regulation of epithelial cell proliferation	Biological Process	IDA[10572067]	9
GO:0048471	perinuclear region of cytoplasm	Cellular Component		87
GO:0048015	phosphatidylinositol-mediated signaling	Biological Process	NAS[15504738]	16
GO:0046983	protein dimerization activity	Molecular Function	NAS[12000754]	26
GO:0046982	protein heterodimerization activity	Molecular Function	IDA[10572067]; IPI[7556068]; NAS[15504738]	68
GO:0046777	protein autophosphorylation	Biological Process	IDA[7556068]	23
GO:0010008	endosome membrane	Cellular Component	IDA[16314522]	27
GO:0014065	phosphatidylinositol 3-kinase cascade	Biological Process	IDA[7556068]	4
GO:0016021	integral to membrane	Cellular Component	NAS[15609325]	845
GO:0016323	basolateral plasma membrane	Cellular Component	IDA[12646923]	29
GO:0016324	apical plasma membrane	Cellular Component		51
GO:0019838	growth factor binding	Molecular Function	IDA[7514177]	8
GO:0019903	protein phosphatase binding	Molecular Function	IPI[15899872]	12
GO:0023014	signal transduction by phosphorylation	Biological Process	TAS[10851066]	1
GO:0007399	nervous system development	Biological Process	TAS[15504738]	54
GO:0007411	axon guidance	Biological Process		65
GO:0007422	peripheral nervous system development	Biological Process		7
GO:0007507	heart development	Biological Process	TAS[15504738]	23
GO:0007528	neuromuscular junction development	Biological Process		8
GO:0008022	protein C-terminus binding	Molecular Function	IPI[15520177]	32
GO:0008045	motor neuron axon guidance	Biological Process		7
GO:0008283	cell proliferation	Biological Process	TAS[10851066]	60
GO:0043235	receptor complex	Cellular Component	IDA[7514177]; TAS[7556068]	11
GO:0043125	ErbB-3 class receptor binding	Molecular Function	TAS[9590694]	2
GO:0045727	positive regulation of translation	Biological Process		4
GO:0043406	positive regulation of MAP kinase activity	Biological Process	IDA[10572067]	10
GO:0045785	positive regulation of cell adhesion	Biological Process	IDA[7556068]	7
GO:0045765	regulation of angiogenesis	Biological Process	NAS[15609325]	3
GO:0045945	positive regulation of transcription from RNA polymerase III promoter	Biological Process	IDA[19372587]	2
GO:0045943	positive regulation of transcription from RNA polymerase I promoter	Biological Process		1
GO:0030879	mammary gland development	Biological Process	TAS[15504738]	2
GO:0030307	positive regulation of cell growth	Biological Process		8
GO:0032886	regulation of microtubule-based process	Biological Process		5
GO:0032321	positive regulation of Rho GTPase activity	Biological Process		6
GO:0042060	wound healing	Biological Process	IDA[12646923]	13
GO:0033088	negative regulation of immature T cell proliferation in thymus	Biological Process		2
GO:0042802	identical protein binding	Molecular Function		70
GO:0042552	myelination	Biological Process		7
GO:0001042	RNA polymerase I core binding	Molecular Function		1
GO:0001934	positive regulation of protein phosphorylation	Biological Process		22
GO:0007165	signal transduction	Biological Process	IDA[10572067]	171
GO:0006468	protein phosphorylation	Biological Process	TAS[10851066]	53
GO:0006351	transcription, DNA-dependent	Biological Process		247
GO:0005886	plasma membrane	Cellular Component	NAS[12000754]	772
GO:0007173	epidermal growth factor receptor signaling pathway	Biological Process	NAS[15504738]	25
GO:0007169	transmembrane receptor protein tyrosine kinase signaling pathway	Biological Process	IDA[7514177]; TAS[7556068]	16
GO:0007167	enzyme linked receptor protein signaling pathway	Biological Process	TAS[9590694]	2
GO:0007166	cell surface receptor signaling pathway	Biological Process	IDA[9685399]	35
GO:0004888	transmembrane signaling receptor activity	Molecular Function	IDA[7514177]	20
GO:0004716	receptor signaling protein tyrosine kinase activity	Molecular Function		2
GO:0004714	transmembrane receptor protein tyrosine kinase activity	Molecular Function	IDA[7514177]	5
GO:0004713	protein tyrosine kinase activity	Molecular Function	IDA[7556068]; IGI[7556068]	10
GO:0005634	nucleus	Cellular Component	IDA[16314522]	770
GO:0005524	ATP binding	Molecular Function		228
GO:0005515	protein binding	Molecular Function		910
GO:0005006	epidermal growth factor-activated receptor activity	Molecular Function	NAS[15504738]	1

Gene related KEGG pathways (count: 10)

ID	Name	No. of Genes in ADHDgene	Brief Description
hsa05219	Bladder cancer	7	The urothelium covers the luminal surface of almost the enti...... The urothelium covers the luminal surface of almost the entire urinary tract, extending from the renal pelvis, through the ureter and bladder, to the proximal urethra. The majority of urothelial carcinoma are bladder carcinomas, and urothelial carcinomas of the renal pelvis and ureter account for only approximately 7% of the total. Urothelial tumours arise and evolve through divergent phenotypic pathways. Some tumours progress from urothelial hyperplasia to low-grade non-invasive superficial papillary tumours. More aggressive variants arise either from flat, high-grade carcinoma in situ (CIS) and progress to invasive tumours, or they arise de novo as invasive tumours. Low-grade papillary tumors frequently show a constitutive activation of the receptor tyrosine kinase-Ras pathway, exhibiting activating mutations in the HRAS and fibroblast growth factor receptor 3 (FGFR3) genes. In contrast, CIS and invasive tumors frequently show alterations in the TP53 and RB genes and pathways. Invasion and metastases are promoted by several factors that alter the tumour microenvironment, including the aberrant expression of E-cadherins (E-cad), matrix metalloproteinases (MMPs), angiogenic factors such as vascular endothelial growth factor (VEGF). More...
hsa05223	Non-small cell lung cancer	10	Lung cancer is a leading cause of cancer death among men and...... Lung cancer is a leading cause of cancer death among men and women in industrialized countries. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer and represents a heterogeneous group of cancers, consisting mainly of squamous cell (SCC), adeno (AC) and large-cell carcinoma. Molecular mechanisms altered in NSCLC include activation of oncogenes, such as K-RAS and c-erbB-2, and inactivation of tumorsuppressor genes, such as p53, p16INK4a, RAR-beta, and RASSF1. Point mutations within the K-RAS gene inactivate GTPase activity and the p21-RAS protein continuously transmits growth signals to the nucleus. Overexpression of c-erbB-2 or EGFR leads to a proliferative advantage. Inactivating mutation of p53 can lead to more rapid proliferation and reduced apoptosis. The protein encoded by the p16INK4a inhibits formation of CDK-cyclin-D complexes by competitive binding of CDK4 and CDK6. Loss of p16INK4a expression is a common feature of NSCLC. RAR-beta is a nuclear receptor that bears vitamin-A-dependent transcriptional activity. RASSF1A is able to form heterodimers with Nore-1, an RAS effector.Therefore loss of RASSF1A might shift the balance of RAS activity towards a growth-promoting effect. More...
hsa05215	Prostate cancer	13	Prostate cancer constitutes a major health problem in Wester...... Prostate cancer constitutes a major health problem in Western countries. It is the most frequently diagnosed cancer among men and the second leading cause of male cancer deaths. The identification of key molecular alterations in prostate-cancer cells implicates carcinogen defenses (GSTP1), growth-factor-signaling pathways (NKX3.1, PTEN, and p27), and androgens (AR) as critical determinants of the phenotype of prostate-cancer cells. Glutathione S-transferases (GSTP1) are detoxifying enzymes. Cells of prostatic intraepithelial neoplasia, devoid of GSTP1, undergo genomic damage mediated by carcinogens. NKX3.1, PTEN, and p27 regulate the growth and survival of prostate cells in the normal prostate. Inadequate levels of PTEN and NKX3.1 lead to a reduction in p27 levels and to increased proliferation and decreased apoptosis. Androgen receptor (AR) is a transcription factor that is normally activated by its androgen ligand. During androgen withdrawal therapy, the AR signal transduction pathway also could be activated by amplification of the AR gene, by AR gene mutations, or by altered activity of AR coactivators. Through these mechanisms, tumor cells lead to the emergence of androgen-independent prostate cancer. More...
hsa05212	Pancreatic cancer	13	Infiltrating ductal adenocarcinoma is the most common malign...... Infiltrating ductal adenocarcinoma is the most common malignancy of the pancreas. When most investigators use the term 'pancreatic cancer' they are referring to pancreatic ductal adenocarcinoma (PDA). Normal duct epithelium progresses to infiltrating cancer through a series of histologically defined precursors (PanINs). The overexpression of HER-2/neu and activating point mutations in the K-ras gene occur early, inactivation of the p16 gene at an intermediate stage, and the inactivation of p53, SMAD4, and BRCA2 occur relatively late. Activated K-ras engages multiple effector pathways. Although EGF receptors are conventionally regarded as upstream activators of RAS proteins, they can also act as RAS signal transducers via RAS-induced autocrine activation of the EGFR family ligands. Moreover, PDA shows extensive genomic instability and aneuploidy. Telomere attrition and mutations in p53 and BRCA2 are likely to contribute to these phenotypes. Inactivation of the SMAD4 tumour suppressor gene leads to loss of the inhibitory influence of the transforming growth factor-beta signalling pathway. More...
hsa04020	Calcium signaling pathway	63	Ca2+ that enters the cell from the outside is a principal so...... Ca2+ that enters the cell from the outside is a principal source of signal Ca2+. Entry of Ca2+ is driven by the presence of a large electrochemical gradient across the plasma membrane. Cells use this external source of signal Ca2+ by activating various entry channels with widely different properties. The voltage-operated channels (VOCs) are found in excitable cells and generate the rapid Ca2+ fluxes that control fast cellular processes. There are many other Ca2+-entry channels, such as the receptor-operated channels (ROCs), for example the NMDA (N-methyl-D-aspartate) receptors (NMDARs) that respond to glutamate. There also are second-messenger-operated channels (SMOCs) and store-operated channels (SOCs). More...
hsa04520	Adherens junction	14	Cell-cell adherens junctions (AJs), the most common type of ...... Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion. More...
hsa04510	Focal adhesion	40	Cell-matrix adhesions play essential roles in important biol...... Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins. Some of the constituents of focal adhesions participate in the structural link between membrane receptors and the actin cytoskeleton, while others are signalling molecules, including different protein kinases and phosphatases, their substrates, and various adapter proteins. Integrin signaling is dependent upon the non-receptor tyrosine kinase activities of the FAK and src proteins as well as the adaptor protein functions of FAK, src and Shc to initiate downstream signaling events. These signalling events culminate in reorganization of the actin cytoskeleton; a prerequisite for changes in cell shape and motility, and gene expression. Similar morphological alterations and modulation of gene expression are initiated by the binding of growth factors to their respective receptors, emphasizing the considerable crosstalk between adhesion- and growth factor-mediated signalling. More...
hsa05213	Endometrial cancer	12	Endometrial cancer (EC) is the most common gynaecological ma...... Endometrial cancer (EC) is the most common gynaecological malignancy and the fourth most common malignancy in women in the developed world after breast, colorectal and lung cancer. Two types of endometrial carcinoma are distinguished with respect to biology and clinical course. Type-I carcinoma is related to hyperestrogenism by association with endometrial hyperplasia, frequent expression of estrogen and progesterone receptors and younger age, whereas type-II carcinoma is unrelated to estrogen, associated with atrophic endometrium, frequent lack of estrogen and progesterone receptors and older age. The morphologic differences in these cancers are mirrored in their molecular genetic profile with type I showing defects in DNA-mismatch repair and mutations in PTEN, K-ras, and beta-catenin, and type II showing aneuploidy, p53 mutations, and her2/neu amplification. More...
hsa04012	ErbB signaling pathway	21	The ErbB family of receptor tyrosine kinases (RTKs) couples ...... The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues (pY) within the cytoplasmic tail. Signaling effectors containing binding pockets for pY-containing peptides are recruited to activated receptors and induce the various signaling pathways. The Shc- and/or Grb2-activated mitogen-activated protein kinase (MAPK) pathway is a common target downstream of all ErbB receptors. Similarly, the phosphatidylinositol-3-kinase (PI-3K) pathway is directly or indirectly activated by most ErbBs. Several cytoplasmic docking proteins appear to be recruited by specific ErbB receptors and less exploited by others. These include the adaptors Crk, Nck, the phospholipase C gamma (PLCgamma), the intracellular tyrosine kinase Src, or the Cbl E3 ubiquitin protein ligase. More...
hsa05200	Pathways in cancer	52

Genes shared at least 5 GO terms with ERBB2 (count: 94)

Gene Symbol	Pathway Count	Pathway List
ROS1	10	regulation of ERK1 and ERK2 cascade; integral to membrane; protein phosphatase binding; cell proliferation; protein phosphorylation; plasma membrane; transmembrane receptor protein tyrosine kinase signaling pathway; transmembrane receptor protein tyrosine kinase activity; protein tyrosine kinase activity; ATP binding;
GSK3B	10	perinuclear region of cytoplasm; phosphatidylinositol-mediated signaling; axon guidance; regulation of microtubule-based process; protein phosphorylation; plasma membrane; epidermal growth factor receptor signaling pathway; nucleus; ATP binding; protein binding;
FLT4	10	protein autophosphorylation; growth factor binding; protein phosphatase binding; positive regulation of protein phosphorylation; plasma membrane; transmembrane receptor protein tyrosine kinase signaling pathway; transmembrane receptor protein tyrosine kinase activity; nucleus; ATP binding; protein binding;
TGFBR1	10	growth factor binding; heart development; receptor complex; positive regulation of cell growth; wound healing; signal transduction; protein phosphorylation; plasma membrane; ATP binding; protein binding;
SYK	9	regulation of ERK1 and ERK2 cascade; protein autophosphorylation; cell proliferation; protein phosphorylation; plasma membrane; enzyme linked receptor protein signaling pathway; receptor signaling protein tyrosine kinase activity; ATP binding; protein binding;
PAK1	9	protein autophosphorylation; axon guidance; neuromuscular junction development; wound healing; identical protein binding; protein phosphorylation; plasma membrane; ATP binding; protein binding;
VEGFA	8	positive regulation of epithelial cell proliferation; protein heterodimerization activity; nervous system development; positive regulation of MAP kinase activity; positive regulation of cell adhesion; identical protein binding; positive regulation of protein phosphorylation; protein binding;
PIK3R1	8	phosphatidylinositol-mediated signaling; phosphatidylinositol 3-kinase cascade; protein phosphatase binding; ErbB-3 class receptor binding; protein phosphorylation; plasma membrane; epidermal growth factor receptor signaling pathway; protein binding;
MUSK	8	protein autophosphorylation; neuromuscular junction development; positive regulation of protein phosphorylation; transmembrane receptor protein tyrosine kinase signaling pathway; transmembrane receptor protein tyrosine kinase activity; protein tyrosine kinase activity; ATP binding; protein binding;
PRKD1	8	protein autophosphorylation; cell proliferation; identical protein binding; signal transduction; plasma membrane; nucleus; ATP binding; protein binding;
PRKAA1	8	apical plasma membrane; protein C-terminus binding; signal transduction; protein phosphorylation; transcription, DNA-dependent; nucleus; ATP binding; protein binding;
MAPK1	8	axon guidance; positive regulation of translation; signal transduction; transcription, DNA-dependent; epidermal growth factor receptor signaling pathway; nucleus; ATP binding; protein binding;
TBX1	7	positive regulation of epithelial cell proliferation; protein dimerization activity; heart development; cell proliferation; positive regulation of protein phosphorylation; transcription, DNA-dependent; nucleus;
ADRA2A	7	protein heterodimerization activity; basolateral plasma membrane; receptor complex; positive regulation of MAP kinase activity; signal transduction; plasma membrane; protein binding;
MAP3K11	7	protein autophosphorylation; cell proliferation; identical protein binding; protein phosphorylation; protein tyrosine kinase activity; ATP binding; protein binding;
GHR	7	integral to membrane; growth factor binding; protein phosphatase binding; receptor complex; plasma membrane; nucleus; protein binding;
MAPK3	7	axon guidance; positive regulation of protein phosphorylation; protein phosphorylation; epidermal growth factor receptor signaling pathway; nucleus; ATP binding; protein binding;
PRKCB	7	signal transduction; protein phosphorylation; transcription, DNA-dependent; plasma membrane; nucleus; ATP binding; protein binding;
AATK	6	perinuclear region of cytoplasm; protein autophosphorylation; integral to membrane; protein tyrosine kinase activity; ATP binding; protein binding;
ACHE	6	perinuclear region of cytoplasm; nervous system development; cell proliferation; plasma membrane; nucleus; protein binding;
EHD3	6	perinuclear region of cytoplasm; endosome membrane; plasma membrane; nucleus; ATP binding; protein binding;
LPXN	6	perinuclear region of cytoplasm; signal transduction; transcription, DNA-dependent; plasma membrane; nucleus; protein binding;
ATM	6	protein dimerization activity; protein autophosphorylation; heart development; signal transduction; ATP binding; protein binding;
FES	6	protein autophosphorylation; axon guidance; cell proliferation; protein phosphorylation; protein tyrosine kinase activity; ATP binding;
MARK2	6	protein autophosphorylation; protein phosphorylation; plasma membrane; nucleus; ATP binding; protein binding;
NEK6	6	protein autophosphorylation; signal transduction; protein phosphorylation; nucleus; ATP binding; protein binding;
ADCY4	6	integral to membrane; signal transduction; plasma membrane; epidermal growth factor receptor signaling pathway; ATP binding; protein binding;
ADAM17	6	apical plasma membrane; positive regulation of cell growth; positive regulation of protein phosphorylation; plasma membrane; epidermal growth factor receptor signaling pathway; protein binding;
ADRB2	6	apical plasma membrane; receptor complex; plasma membrane; cell surface receptor signaling pathway; nucleus; protein binding;
DAB2	6	apical plasma membrane; protein C-terminus binding; cell proliferation; positive regulation of protein phosphorylation; nucleus; protein binding;
NTF3	6	nervous system development; axon guidance; peripheral nervous system development; myelination; signal transduction; transmembrane receptor protein tyrosine kinase signaling pathway;
APBB1	6	axon guidance; signal transduction; transcription, DNA-dependent; plasma membrane; nucleus; protein binding;
ROCK2	6	axon guidance; protein phosphorylation; plasma membrane; nucleus; ATP binding; protein binding;
SEMA4D	6	axon guidance; positive regulation of Rho GTPase activity; positive regulation of protein phosphorylation; plasma membrane; transmembrane signaling receptor activity; protein binding;
ADRBK1	6	heart development; signal transduction; plasma membrane; epidermal growth factor receptor signaling pathway; ATP binding; protein binding;
XRCC5	6	protein C-terminus binding; cell proliferation; transcription, DNA-dependent; nucleus; ATP binding; protein binding;
ILK	6	cell proliferation; positive regulation of MAP kinase activity; protein phosphorylation; plasma membrane; ATP binding; protein binding;
BAD	5	positive regulation of epithelial cell proliferation; phosphatidylinositol-mediated signaling; protein heterodimerization activity; epidermal growth factor receptor signaling pathway; protein binding;
ALG2	5	perinuclear region of cytoplasm; protein heterodimerization activity; integral to membrane; nucleus; protein binding;
EHD1	5	perinuclear region of cytoplasm; endosome membrane; plasma membrane; ATP binding; protein binding;
MAP1S	5	perinuclear region of cytoplasm; nervous system development; identical protein binding; nucleus; protein binding;
NOX4	5	perinuclear region of cytoplasm; integral to membrane; apical plasma membrane; positive regulation of MAP kinase activity; nucleus;
SIPA1	5	perinuclear region of cytoplasm; cell proliferation; signal transduction; nucleus; protein binding;
SNCA	5	perinuclear region of cytoplasm; identical protein binding; plasma membrane; nucleus; protein binding;
STX4	5	perinuclear region of cytoplasm; integral to membrane; basolateral plasma membrane; plasma membrane; protein binding;
TLR4	5	perinuclear region of cytoplasm; endosome membrane; plasma membrane; transmembrane signaling receptor activity; protein binding;
TPD52L1	5	perinuclear region of cytoplasm; protein heterodimerization activity; positive regulation of MAP kinase activity; identical protein binding; protein binding;
TYR	5	perinuclear region of cytoplasm; protein heterodimerization activity; integral to membrane; cell proliferation; protein binding;
POU2F3	5	protein dimerization activity; wound healing; transcription, DNA-dependent; nucleus; protein binding;
SREBF1	5	protein dimerization activity; integral to membrane; transcription, DNA-dependent; nucleus; protein binding;
ADRB1	5	protein heterodimerization activity; wound healing; plasma membrane; nucleus; protein binding;
BDKRB2	5	protein heterodimerization activity; plasma membrane; transmembrane receptor protein tyrosine kinase signaling pathway; cell surface receptor signaling pathway; protein binding;
CD3D	5	protein heterodimerization activity; integral to membrane; plasma membrane; cell surface receptor signaling pathway; transmembrane signaling receptor activity;
CD3E	5	protein heterodimerization activity; plasma membrane; transmembrane receptor protein tyrosine kinase signaling pathway; cell surface receptor signaling pathway; transmembrane signaling receptor activity;
INHA	5	protein heterodimerization activity; nervous system development; signal transduction; cell surface receptor signaling pathway; protein binding;
JAM3	5	protein heterodimerization activity; integral to membrane; myelination; plasma membrane; protein binding;
NR4A2	5	protein heterodimerization activity; signal transduction; transcription, DNA-dependent; nucleus; protein binding;
SMC3	5	protein heterodimerization activity; signal transduction; nucleus; ATP binding; protein binding;
SIK2	5	protein autophosphorylation; protein phosphorylation; nucleus; ATP binding; protein binding;
TSSK2	5	protein autophosphorylation; identical protein binding; protein phosphorylation; ATP binding; protein binding;
UBB	5	endosome membrane; transcription, DNA-dependent; plasma membrane; epidermal growth factor receptor signaling pathway; protein binding;
UBC	5	endosome membrane; transcription, DNA-dependent; plasma membrane; epidermal growth factor receptor signaling pathway; protein binding;
PIK3CG	5	phosphatidylinositol 3-kinase cascade; positive regulation of MAP kinase activity; plasma membrane; ATP binding; protein binding;
APLP2	5	integral to membrane; identical protein binding; plasma membrane; nucleus; protein binding;
ATF6	5	integral to membrane; signal transduction; transcription, DNA-dependent; nucleus; protein binding;
CADM1	5	integral to membrane; basolateral plasma membrane; protein C-terminus binding; plasma membrane; protein binding;
ENPP1	5	integral to membrane; basolateral plasma membrane; plasma membrane; ATP binding; protein binding;
IL5RA	5	integral to membrane; cell proliferation; signal transduction; plasma membrane; protein binding;
IL7R	5	integral to membrane; signal transduction; plasma membrane; cell surface receptor signaling pathway; protein binding;
ANK3	5	basolateral plasma membrane; axon guidance; signal transduction; plasma membrane; protein binding;
CHRM3	5	basolateral plasma membrane; nervous system development; cell proliferation; signal transduction; plasma membrane;
STXBP3	5	basolateral plasma membrane; apical plasma membrane; plasma membrane; nucleus; protein binding;
TJP1	5	basolateral plasma membrane; protein C-terminus binding; plasma membrane; nucleus; protein binding;
AKAP7	5	apical plasma membrane; protein C-terminus binding; plasma membrane; nucleus; protein binding;
CTNND1	5	protein phosphatase binding; transcription, DNA-dependent; plasma membrane; nucleus; protein binding;
RPS6KA4	5	axon guidance; protein phosphorylation; nucleus; ATP binding; protein binding;
WASL	5	axon guidance; transcription, DNA-dependent; plasma membrane; nucleus; protein binding;
EDNRA	5	heart development; cell proliferation; positive regulation of protein phosphorylation; signal transduction; plasma membrane;
PLCE1	5	heart development; cell proliferation; plasma membrane; epidermal growth factor receptor signaling pathway; protein binding;
ATXN1	5	protein C-terminus binding; identical protein binding; transcription, DNA-dependent; nucleus; protein binding;
BAIAP2	5	protein C-terminus binding; identical protein binding; plasma membrane; nucleus; protein binding;
PLK1	5	cell proliferation; protein phosphorylation; nucleus; ATP binding; protein binding;
BMPR1B	5	receptor complex; protein phosphorylation; plasma membrane; ATP binding; protein binding;
APC	5	positive regulation of cell adhesion; regulation of microtubule-based process; plasma membrane; nucleus; protein binding;
FLCN	5	positive regulation of cell adhesion; positive regulation of protein phosphorylation; plasma membrane; nucleus; protein binding;
MAPK7	5	regulation of angiogenesis; signal transduction; nucleus; ATP binding; protein binding;
ELK3	5	wound healing; signal transduction; transcription, DNA-dependent; nucleus; protein binding;
RIPK3	5	identical protein binding; signal transduction; plasma membrane; ATP binding; protein binding;
CSNK1E	5	signal transduction; protein phosphorylation; nucleus; ATP binding; protein binding;
PRKG1	5	signal transduction; protein phosphorylation; plasma membrane; ATP binding; protein binding;
ROR2	5	signal transduction; transmembrane receptor protein tyrosine kinase signaling pathway; transmembrane receptor protein tyrosine kinase activity; ATP binding; protein binding;
FRK	5	protein phosphorylation; plasma membrane; nucleus; ATP binding; protein binding;
HSPA8	5	transcription, DNA-dependent; plasma membrane; nucleus; ATP binding; protein binding;
CBL	5	plasma membrane; epidermal growth factor receptor signaling pathway; cell surface receptor signaling pathway; nucleus; protein binding;

Genes shared at least 2 KEGG pathways with ERBB2 (count: 37)

Gene Symbol	Pathway Count	Pathway List
MAPK1	9	Bladder cancer; Non-small cell lung cancer; Prostate cancer; Pancreatic cancer; Adherens junction; Focal adhesion; Endometrial cancer; ErbB signaling pathway; Pathways in cancer;
MAPK3	9	Bladder cancer; Non-small cell lung cancer; Prostate cancer; Pancreatic cancer; Adherens junction; Focal adhesion; Endometrial cancer; ErbB signaling pathway; Pathways in cancer;
CCND1	7	Bladder cancer; Non-small cell lung cancer; Prostate cancer; Pancreatic cancer; Focal adhesion; Endometrial cancer; Pathways in cancer;
BAD	7	Non-small cell lung cancer; Prostate cancer; Pancreatic cancer; Focal adhesion; Endometrial cancer; ErbB signaling pathway; Pathways in cancer;
PIK3CG	7	Non-small cell lung cancer; Prostate cancer; Pancreatic cancer; Focal adhesion; Endometrial cancer; ErbB signaling pathway; Pathways in cancer;
PIK3R1	7	Non-small cell lung cancer; Prostate cancer; Pancreatic cancer; Focal adhesion; Endometrial cancer; ErbB signaling pathway; Pathways in cancer;
PRKCB	5	Non-small cell lung cancer; Calcium signaling pathway; Focal adhesion; ErbB signaling pathway; Pathways in cancer;
GSK3B	5	Prostate cancer; Focal adhesion; Endometrial cancer; ErbB signaling pathway; Pathways in cancer;
VEGFA	4	Bladder cancer; Pancreatic cancer; Focal adhesion; Pathways in cancer;
VEGFB	4	Bladder cancer; Pancreatic cancer; Focal adhesion; Pathways in cancer;
PLCG2	4	Non-small cell lung cancer; Calcium signaling pathway; ErbB signaling pathway; Pathways in cancer;
MAPK9	4	Pancreatic cancer; Focal adhesion; ErbB signaling pathway; Pathways in cancer;
RELA	3	Prostate cancer; Pancreatic cancer; Pathways in cancer;
TGFBR1	3	Pancreatic cancer; Adherens junction; Pathways in cancer;
CTNNA2	3	Adherens junction; Endometrial cancer; Pathways in cancer;
CTNNA3	3	Adherens junction; Endometrial cancer; Pathways in cancer;
CRKL	3	Focal adhesion; ErbB signaling pathway; Pathways in cancer;
MMP1	2	Bladder cancer; Pathways in cancer;
GSTP1	2	Prostate cancer; Pathways in cancer;
PDGFD	2	Prostate cancer; Focal adhesion;
PLD1	2	Pancreatic cancer; Pathways in cancer;
CAMK2D	2	Calcium signaling pathway; ErbB signaling pathway;
ACTN3	2	Adherens junction; Focal adhesion;
BIRC2	2	Focal adhesion; Pathways in cancer;
BIRC3	2	Focal adhesion; Pathways in cancer;
FN1	2	Focal adhesion; Pathways in cancer;
ILK	2	Focal adhesion; Endometrial cancer;
ITGA2	2	Focal adhesion; Pathways in cancer;
LAMA2	2	Focal adhesion; Pathways in cancer;
LAMA3	2	Focal adhesion; Pathways in cancer;
LAMC1	2	Focal adhesion; Pathways in cancer;
LAMC2	2	Focal adhesion; Pathways in cancer;
PAK1	2	Focal adhesion; ErbB signaling pathway;
PAK7	2	Focal adhesion; ErbB signaling pathway;
SHC3	2	Focal adhesion; ErbB signaling pathway;
APC	2	Endometrial cancer; Pathways in cancer;
CBL	2	ErbB signaling pathway; Pathways in cancer;

View in gBrowse

Region: chr17:37844393..37884915 View in gBrowse